ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "large vessel vasculitis"

  • Abstract Number: 2920 • 2019 ACR/ARP Annual Meeting

    Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis

    K Bates Gribbons1, Cristina Ponte 2, Anthea Craven 3, David Cuthbertson 4, Simon Carette 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Curry L. Koening 8, Carol Langford 9, Kathleen Maksimowicz-McKinnon 10, Carol A. McAlear 11, Paul Monach 12, Larry Moreland 13, Christian Pagnoux 14, Kaitlin Quinn 15, Joanna Robson 16, Philip Seo 17, Antoine Sreih 18, Ravi Suppiah 19, Kenneth Warrington 20, Steven Ytterberg 21, Raashid Luqmani 3, Richard Watts 22, Peter Merkel 18 and Peter C. Grayson 23, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, 3University of Oxford, Oxford, United Kingdom, 4University of South Florida, Tampa, FL, 5Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, Canada, 6Cleveland Clinic Foundation, Cleveland, OH, 7McMaster University, Hamilton, ON, Canada, 8University of Utah Hospital, Salt Lake City, UT, 9Cleveland Clinic, Cleveland, OH, 10Henry Ford Hospital, Wayne State University, Detroit, MI, 11University of Pennsylvania - VCRC Project Manager, Philadelphia, PA, 12Brigham and Women's Hospital, Boston, MA, 13University of Pittsburgh, PITTSBURGH, PA, 14Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, 15Georgetown University Hospital/National Institutes of Health, Washington, DC, 16Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, 17Johns Hopkins Medicine, Baltimore, MD, 18University of Pennsylvania, Philadelphia, PA, 19Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 20Mayo Clinic Rochester, Rochester, MN, 21Mayo Clinic College of Medicine, Rochester, MN, 22Norwich Medical School, University of East Anglia, Norwich, United Kingdom, 23National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: Current classification criteria differentiate between Takayasu’s arteritis (TAK) and giant cell arteritis (GCA), the two most common forms of large-vessel vasculitis, based primarily on…
  • Abstract Number: 2922 • 2019 ACR/ARP Annual Meeting

    Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis

    Kaitlin Quinn1, Joel S. Rosenblum 2, Casey A. Rimland 3, K Bates Gribbons 4, Mark A. Ahlman 5 and Peter C. Grayson 6, 1Georgetown University Hospital/National Institutes of Health, Washington, DC, 2National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, Bethesda, MD, 3National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, Chapel Hill, NC, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 5Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD

    Background/Purpose: 18F-flurodeoxyglucose (FDG) positron emission tomography (PET) is one of several imaging modalities used in the assessment of patients with large-vessel vasculitis (LVV).  Conventionally PET…
  • Abstract Number: 293 • 2019 ACR/ARP Annual Meeting

    False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign

    Elisa Fernández1, Irene Monjo 2, Gema Bonilla 3, Chamaida Plasencia 4, Maria-Eugenia Miranda-Carus 2, Alejandro Balsa 4 and Eugenio de Miguel 5, 1Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain, 2FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, 3Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, Madrid, Spain, 4Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain

    Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in the elderly. The halo sign is an accepted valid test for the diagnosis…
  • Abstract Number: 372 • 2019 ACR/ARP Annual Meeting

    Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience

    Gozde Kubra Yardımcı 1, Alper Sarı 1, Abdulsamet Erden 2, Ertugrul Cagri Bolek 1, Bayram Farisoğulları 1, Levent Kilic 3, Berkan Armagan 4, Umut Kalyoncu 5, Tuncay Hazırolan 6, Ali İhsan Ertenli 1 and Omer Karadag7, 1Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, 2Ministry of Health Ankara City Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 3Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, 4Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey., Ankara, Turkey, 5Hacettepe University Department of Rheumatology, Ankara, Turkey, 6Hacettepe University, Division of Radiology, Ankara, 7Hacettepe University Vasculitis Centre, Ankara, Turkey / Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, UK, Ankara, Turkey

    Background/Purpose: Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that may involve multiple organ systems. IgG4-RD can also lead to large vessel vasculitis and…
  • Abstract Number: 819 • 2018 ACR/ARHP Annual Meeting

    Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis

    Sivakumar Mambakkam Rajappa1 and Krishnamurthy Venkataraman2, 1Rheumatology and Immunology, GLB Hospitals, Chennai, India, 2Rheumatology, Apollo Speciality Hospitals, Chennai, India

    Background/Purpose: Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars…
  • Abstract Number: 2196 • 2018 ACR/ARHP Annual Meeting

    Kinetics of Tissue-Specific Distribution of 18f-Fluorodeoxyglucose in Positron Emission Tomography in Large Vessel Vasculitis

    Joel S. Rosenblum1, Kaitlin Quinn2, Mark A. Ahlman3 and Peter C. Grayson4, 1NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 2Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 3Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 4National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

    Background/Purpose: 18F-fluorodeoxyglucose (FDG) PET may be used to quantify vascular inflammation in large-vessel vasculitis (LVV).  Quantitative analysis of arterial FDG uptake has not been standardized. Delayed…
  • Abstract Number: 2746 • 2018 ACR/ARHP Annual Meeting

    Tocilizumab Monotherapy for Large Vessel Vasculitis: Results of 104-Week Treatment of a Prospective, Single-Center, Open Study

    Shuntaro Saito, Ayumi Okuyama, Yusuke Okada, Akiko Shibata, Ryota Sakai, Kentaro Chino, Takahiko Kurasawa, Tsuneo Kondo, Hirofumi Takei and Koichi Amano, Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA).…
  • Abstract Number: 2759 • 2018 ACR/ARHP Annual Meeting

    Effect of Specific Treatments on Clinical, Serologic, and Imaging Assessments of Disease Activity in Large-Vessel Vasculitis

    Shubhasree Banerjee1, Kaitlin Quinn2, Katherine B. Gribbons3, Joel S. Rosenblum4, Ali Civelek5, Elaine Novakovich6, Armin Bagheri1, Peter A. Merkel7, Mark A. Ahlman8 and Peter C. Grayson9, 1Systemic Autoimmunity Branch, NIAMS, NIH, Bethesda, MD, 2Systemic Autoimmunity Branch, NIAMS, Bethesda, MD, 3Systemic Autoimmunity Branch, National Institute of Arthritis and Skin and Musculoskeletal Disease, Bethesda, MD, 4NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, 5National Institutes of Health, Clinical Center, Radiology and Imaging Sciences, Bethesda, MD, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 7University of Pennsylvania, Philadelphia, PA, 8Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 9National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD

    Background/Purpose: Disease activity in large vessel vasculitis (LVV) is traditionally assessed by clinical and serologic (ESR, CRP) parameters. Imaging assessment, including 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET),…
  • Abstract Number: 2778 • 2018 ACR/ARHP Annual Meeting

    High Prevalence of Vascular Surgery and Autoimmune Comorbidity in Takayasu Arteritis

    Tsuyoshi Shirai1, Tomoyuki Muto2, Yuko Shirota1, Hiroshi Fujii1, Tomonori Ishii3 and Hideo Harigae1, 1Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 2Tohoku University Graduate School of Medicine, Sendai, Japan, 3Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan

    Background/Purpose: Large vessel vasculitis (LVV) is the arteritis in aorta and its major branches, and classified into Takayasu arteritis (TAK) and giant cell arteritis (GCA).…
  • Abstract Number: 102 • 2017 ACR/ARHP Annual Meeting

    Incorporating Temporal Artery Ultrasound in a UK District General Hospital with No Prior Colour Doppler Sonography Service: An Encouraging Preliminary Analysis

    Othman Kirresh1, Chintu Gademsetty2 and Charles Li1, 1Rheumatology, NHS Royal Surrey County Hospital, Surrey, United Kingdom, 2Radiology, NHS Royal Surrey County Hospital, Surrey, United Kingdom

    Background/Purpose: Temporal Arteritis (TA) is the most common large vessel vasculitis, affecting adults over the age of 50. It is associated with significant morbidity due…
  • Abstract Number: 785 • 2017 ACR/ARHP Annual Meeting

    Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis

    Antoine G. Sreih1, Tanaz A. Kermani2, David Cuthbertson3, Simon Carette4, Lindsy J. Forbess5, Nader A. Khalidi6, Curry L. Koening7, Carol A. McAlear8, Paul A. Monach9, Larry W. Moreland10, Christian Pagnoux11, Philip Seo12, Robert F. Spiera13, Kenneth J. Warrington14, Steven R. Ytterberg14, Carol A. Langford15 and Peter A. Merkel16,17, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Division of Rheumatology, University of California, Los Angeles, CA, 3Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 4Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 6Rheumatology, McMaster University, Hamilton, ON, Canada, 7Rheumatology, University of Utah, Salt Lake City, UT, 8University of Pennsylvania, Philadelphia, PA, 9Boston University School of Medicine, Boston, MA, 10Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 11Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 12Medicine, Johns Hopkins University, Baltimore, MD, 13Rheumatology, Hospital for Special Surgery, New York, NY, 14Rheumatology, Mayo Clinic, Rochester, MN, 15Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 16Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA, 17Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

    Background/Purpose : Longitudinal data on the type, progression, and predictors of arterial lesions in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to…
  • Abstract Number: 788 • 2017 ACR/ARHP Annual Meeting

    Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis

    Mingcai Zhang1, Mehrdad Maz2, Don Smith3, Noriko Miura4, Naohito Ohno5, Kottarappat Dileepan6 and Jason Springer7, 1Department of Orthopedics, University of Kansas Medical Center, Kansas City, KS, 2Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS, 3University of Kansas Medical Center, Kansas City, KS, 4School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan, 5Tokyo University of Pharmacy and Lift Sciences, Tokyo, Japan, 6Department of Medicine, University of Kansas Medical Center, Kansas, KS, 7Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS

    Background/Purpose: In forms of large vessel vasculitis (LVV) systemic IL-6 has been shown to follow disease activity. Furthermore, IL-6 inhibition is an effective treatment for…
  • Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting

    Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan

    Takahiko Sugihara1, Hitoshi Hasegawa2, Haruhito Uchida3, Hajime Yoshifuji4, Yoshikazu Nakaoka5, Yoshiko Watanabe6, Eisuke Amiya7, Masanori Konishi8, Yasuhiro Katsumata9, Yoshinori Komagata10, Taio Naniwa11,12, Takahiro Okazaki13, Yoshiya Tanaka14, Tsutomu Takeuchi15, Masayoshi Harigai16, Yoshihiro Arimura17 and Mitsuaki Isobe8,18, 1Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, 2Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, 3Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 5Osaka University Graduate School of Medicine, Osaka, Japan, 6First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, 7Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 8Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, 9Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 10First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 11Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, 12Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 13Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, 14The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 15Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 16Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 17First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 18Sakakibara Heart Institute, Tokyo, Japan

    Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
  • Abstract Number: 801 • 2017 ACR/ARHP Annual Meeting

    PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?

    Anna Larissa Faria Janes1, Míriam Fang Castro1, Bruna Savioli1, Anne Elisabeth Diniz Arraes1, Emilia Sato2 and Alexandre W.S. Souza3, 1Internal Medicine - Rheumatology Division, Universidade Federal de São Paulo - Escola Paulista de Medicina, São Paulo, Brazil, 2Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 3Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil

    Background/Purpose: PET-CT scan with 18F-Fluorodeoxyglucose (18F-FDG) has been frequently used as a tool to assess disease activity in Takayasu arteritis (TA) and increased 18F-FDG uptake…
  • Abstract Number: 824 • 2017 ACR/ARHP Annual Meeting

    Long Term Efficacy and Safety of Intravenous and Subcutaneous Biologics in Large Vessels Vasculitis: 21 Patients Belonging to a Single Italian Center from 2011 to 2017

    Paola Toniati1 and Angela Tincani2, 1RHEUMATOLOGY, SPEDALI CIVILI, BRESCIA, Italy, 2University and Spedali Civili of Brescia, Brescia, Italy

    Background/Purpose: Large vessels vasculitis (LVV) is the most common form of primary vasculitis comprising giant cell arteritis (GCA) and Takayasu arteritis (TAK) and aortitis. Methods:…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology